HIG Capital led a $30m Series C funding round in On Target Laboratories.

HIG Capital, a private equity and alternative assets investment firm, led a $30m Series C funding round in On Target Laboratories, a privately held biotechnology company developing intraoperative molecular imaging agents to target and illuminate cancer during surgery, with participation from The Hurvis Group, Johnson & Johnson Innovation, Pension Fund of the Christian Church, 3B Future Health Fund, Elevate Ventures, and Olympus Innovation Ventures. "This investment empowers us to accelerate the commercialization of our novel technology, further solidifying our position at the forefront of intraoperative molecular imaging. This financing is another vote of confidence in our mission to illuminate cancer intraoperatively so it can be removed completely," Ben Lundgren, On Target Laboratories President and CEO.